A. D. Beadell Investment Counsel Inc. Buys 3,787 Shares of Novo Nordisk A/S (NYSE:NVO)

A. D. Beadell Investment Counsel Inc. lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 41.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,012 shares of the company’s stock after purchasing an additional 3,787 shares during the quarter. A. D. Beadell Investment Counsel Inc.’s holdings in Novo Nordisk A/S were worth $1,119,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in NVO. Novare Capital Management LLC increased its position in shares of Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after buying an additional 85 shares during the period. Steel Grove Capital Advisors LLC grew its stake in Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after acquiring an additional 86 shares in the last quarter. Benjamin Edwards Inc. increased its holdings in Novo Nordisk A/S by 2.6% during the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company’s stock worth $493,000 after acquiring an additional 87 shares during the period. Rosenberg Matthew Hamilton increased its holdings in Novo Nordisk A/S by 2.5% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock worth $454,000 after acquiring an additional 94 shares during the period. Finally, Burns J W & Co. Inc. NY lifted its stake in Novo Nordisk A/S by 1.9% in the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock worth $647,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NVO. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Price Performance

Shares of NVO traded up $0.91 during midday trading on Friday, reaching $86.55. The stock had a trading volume of 2,646,449 shares, compared to its average volume of 6,717,778. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $388.40 billion, a price-to-earnings ratio of 28.01, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company’s 50-day moving average is $100.86 and its 200 day moving average is $119.79. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.